2024
Chrenková, Eva; Študentová, Hana; Holá, Kateřina; Kahounová, Zuzana; Hendrychová, Romana; Souček, Karel; Bouchal, Jan
Castration-resistant prostate cancer monitoring by cell-free circulating biomarkers. Journal Article
In: Frontiers in oncology, vol. 14, pp. 1394292, 2024, ISSN: 2234-943X, (Place: Switzerland).
Abstract | Links | BibTeX | Tags: biomarker, castration-resistant prostate cancer, liquid biopsy, progression monitoring, therapy response
@article{chrenkova_castration-resistant_2024,
title = {Castration-resistant prostate cancer monitoring by cell-free circulating biomarkers.},
author = {Eva Chrenková and Hana Študentová and Kateřina Holá and Zuzana Kahounová and Romana Hendrychová and Karel Souček and Jan Bouchal},
doi = {10.3389/fonc.2024.1394292},
issn = {2234-943X},
year = {2024},
date = {2024-01-01},
journal = {Frontiers in oncology},
volume = {14},
pages = {1394292},
abstract = {BACKGROUND: Prostate cancer is the second leading cause of male cancer-related deaths in Western countries, which is predominantly attributed to the metastatic castration-resistant stage of the disease (CRPC). There is an urgent need for better prognostic and predictive biomarkers, particularly for androgen receptor targeted agents and taxanes. METHODS: We have searched the PubMed database for original articles and meta-analyses providing information on blood-based markers for castration-resistant prostate cancer monitoring, risk group stratification and prediction of therapy response. RESULTS: The molecular markers are discussed along with the standard clinical parameters, such as prostate specific antigen, lactate dehydrogenase or C-reactive protein. Androgen receptor (AR) alterations are commonly associated with progression to CRPC. These include amplification of AR and its enhancer, point mutations and splice variants. Among DNA methylations, a novel 5-hydroxymethylcytosine activation marker of TOP2A and EZH2 has been identified for the aggressive disease. miR-375 is currently the most promising candidate among non-coding RNAs and sphingolipid analysis has recently emerged as a novel approach. CONCLUSIONS: The promising biomarkers have the potential to improve the care of metastatic prostate cancer patients, however, they need further validation for routine implementation.},
note = {Place: Switzerland},
keywords = {biomarker, castration-resistant prostate cancer, liquid biopsy, progression monitoring, therapy response},
pubstate = {published},
tppubtype = {article}
}
BACKGROUND: Prostate cancer is the second leading cause of male cancer-related deaths in Western countries, which is predominantly attributed to the metastatic castration-resistant stage of the disease (CRPC). There is an urgent need for better prognostic and predictive biomarkers, particularly for androgen receptor targeted agents and taxanes. METHODS: We have searched the PubMed database for original articles and meta-analyses providing information on blood-based markers for castration-resistant prostate cancer monitoring, risk group stratification and prediction of therapy response. RESULTS: The molecular markers are discussed along with the standard clinical parameters, such as prostate specific antigen, lactate dehydrogenase or C-reactive protein. Androgen receptor (AR) alterations are commonly associated with progression to CRPC. These include amplification of AR and its enhancer, point mutations and splice variants. Among DNA methylations, a novel 5-hydroxymethylcytosine activation marker of TOP2A and EZH2 has been identified for the aggressive disease. miR-375 is currently the most promising candidate among non-coding RNAs and sphingolipid analysis has recently emerged as a novel approach. CONCLUSIONS: The promising biomarkers have the potential to improve the care of metastatic prostate cancer patients, however, they need further validation for routine implementation.